Arpida AG
๐จ๐ญSwitzerland
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Private, Subsidiary
- Established
- 1997-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.arpida.com
Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- Arpida AG
- Target Recruit Count
- 135
- Registration Number
- NCT00543608
Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2007-03-27
- Lead Sponsor
- Arpida AG
- Registration Number
- NCT00303550
- Locations
- ๐บ๐ธ
Edward Hospital & Health Services, Naperville, Illinois, United States
๐บ๐ธWyoming Medical Center, Casper, Wyoming, United States
Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-03-07
- Last Posted Date
- 2008-04-04
- Lead Sponsor
- Arpida AG
- Registration Number
- NCT00299520
- Locations
- ๐บ๐ธ
Infectious Disease of Indiana, Indianapolis, Indiana, United States
๐บ๐ธVA Medical Center, Boise, Idaho, United States
๐บ๐ธe-Study Site, National City, California, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath